Celularity Celularity
  • Home
  • About
    • About Us
    • Leadership
    • Board of Directors
    • Scientific Advisors
    • Manufacturing
    • Biobanking
    • Tour Our Facility
    • Expanded Access Policy
  • Science
    • Power of Placenta
    • NK Cell Platform
    • T Cell Platform
    • MLASCs
    • Exosomes
    • Advanced Biomaterials
  • Pipeline
  • Newsroom
  • Investors
    • Investor Relations
    • SEC Filings
    • Corporate Governance
  • Careers
Celularity
MENU

COVID-19

Updates

See latest Press Relases
Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy

Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy

10 Mar 2026 8 Minutes 0 1291
...
Avatar photo
Celularity Inc.
Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses

Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses

10 Feb 2026 6 Minutes 0 1291
...
Avatar photo
Celularity Inc.
Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations

Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations

26 Dec 2025 9 Minutes 0 1294
...
Avatar photo
Celularity Inc.
Celularity Announces Closing of Financing Transactions

Celularity Announces Closing of Financing Transactions

22 Dec 2025 10 Minutes 0 1305
...
Avatar photo
Celularity Inc.
Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision

Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision

18 Dec 2025 10 Minutes 0 1294
...
Avatar photo
Celularity Inc.
Load more
Celularity_Nasdaq_CELU-1

Celularity is a biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including mesenchymal-like adherent stromal cells (MLASCs), Natural Killer (NK) cells, and engineered T cells including CAR-T cells, targeting indications across age-related diseases.

Company

  • About
  • Leadership
  • Board of Directors
  • Scientific Advisors
  • Manufacturing
  • Tour Our Facility
  • Careers

Science

  • Pipeline
  • NK Cell Platform
  • T Cell Platform
  • MLASCs
  • Exosomes
  • Lifebank
  • Advanced Biomaterials

Investors

  • Investor Relations
  • Partnerships
  • SEC Filings
  • Corporate Governance
  • Press Releases

Celularity Inc. © 2025. All rights reserved.     Privacy Policy     Terms & Conditions

Company
  • About
  • Leadership
  • Board of Directors
  • Scientific Advisors
  • Manufacturing
  • Tour Our Facility
  • Careers
Science
  • Pipeline
  • NK Cell Platform
  • T Cell Platform
  • MLASCs
  • Exosomes
  • Lifebank
  • Advanced Biomaterials
Investors
  • Investor Relations
  • Partnerships
  • SEC Filings
  • Corporate Governance
  • Press Releases

Celularity Inc. © 2024. All rights reserved.
Privacy Policy     Terms & Conditions